2004 Cardiovascular Biomarkers and Surrogate Endpoints Symposium

Bethesda, Maryland
September 10-11, 2004

2004 Overview

2004 Agenda

2004 Faculty

As a service to our meeting attendees, the following presentation materials are available for viewing. Please note that material availability is at the discretion of our participating faculty.

If you've installed Windows SP 2, please allow your browser to show active content to view these files.

*Login Required to View Materials - Symposium Registrants will receive a username and password at the time of registration

1. The Need for Biomarkers in Drug Development - Dr. Therese Heinonen
2. Pathophysiology of the Complicated Atherosclerotic Plaque - Dr. Peter Libby
3. Acute Coronary Syndromes - Dr. Robert Harrington
4. Biomarkers in Perspective -Dr. Paul Ridker
5. A Tale of Two Trials - Dr. Claude Lenfant
6. Lipoproteins and Other Related Risk Factors - Dr. Daniel Rader
7. HDL Oxidation in the Pathogenesis of Atherosclerosis -Dr. Jay Heinecke
8. The Role of Myeloperoxidase and NO-Derived Oxidants in Atherosclerosis - Dr. Stanley Hazen
9. Markers of Risk and Response to Therapy in a Population with CAD and Low HDL-C - Dr. B. Greg Brown
10. Pharmacogenomics - Dr. Michael Phillips
    
11. Device Development Considerations - Dr. Bram Zuckerman
12. Special Considerations for the Diabetic Population - Dr. George Steiner
13. Markers of CV Disease: Application to Clinical Practice and Public Health - Dr. George Mensah
14. The Role of Imaging in CV Disease Detection and Treatment - Dr. Jean-Claude Tardif
15. Carotid IMT – A CAD Surrogate? - Dr. John Kastelein
16. What’s “New” with IVUS? - Dr. Steve Nissen
17. Endothelial Function and Current Evaluations - Dr. Todd Anderson
18. Practical Considerations in EBCT and Nuclear Imaging - Dr. Paolo Raggi
19. Magnetic Resonance Imaging of the High-Risk Atherosclerotic Plaque - Dr. Thomas Hatsukami
20. CT Angiography – On the Cutting Edge - Dr. Pim de Feyter
21. How Does the FDA Cardio-Renal Department View Surrogate Endpoints? - Dr. Douglas Throckmorton
22. How Does the FDA Metabolism and Endocrine Department View Surrogate Endpoints? - Dr. David Orloff
23. A Perspective from EMEA - Dr. Eric Abadie
24. A Perspective from Health Canada - Dr. Guy Beaulieu
25. The Pharma/Regulatory Interface - Dr. Ray Lipicky